Allurion Technologies (ALUR) Stock Price, News & Analysis

Company Overview

Allurion Technologies is a medical technology company specializing in non-surgical weight-loss solutions. The company’s flagship product, the Allurion Gastric Balloon, is a swallowable, fluid-filled device designed to promote weight loss by creating a sense of fullness in the stomach. Unlike traditional intragastric balloons, the Allurion device does not require endoscopic insertion or removal, as it self-deflates and is naturally expelled after treatment, simplifying the patient experience and reducing clinical resource requirements.

In addition to its gastric balloon, Allurion has developed a comprehensive digital health platform that integrates wireless tracking devices, a mobile application, and remote coaching to support patients throughout their weight-loss journey. The platform provides real-time data on body composition, dietary intake, and physical activity, enabling healthcare providers to monitor patient progress and tailor interventions accordingly. This holistic approach combines medical devices with data-driven behavioral support.

Founded in the early 2010s and headquartered in Natick, Massachusetts, Allurion Technologies has expanded its operations globally, offering its weight-loss solution in multiple markets across North America, Europe, the Middle East, and Asia. The company collaborates with physicians, hospitals, and wellness centers to deliver its programs and has secured regulatory approvals in key jurisdictions, including CE mark certification and other local clearances. Allurion’s strategic partnerships with clinics and healthcare networks aim to make non-surgical weight management more accessible to a wider patient population.

Allurion Technologies continues to invest in research and development to advance its product pipeline and digital offerings. By combining minimally invasive medical devices with a connected health ecosystem, the company seeks to address the growing challenge of obesity and related metabolic conditions through scalable, patient-centric solutions.

Key Stats

• Today's Range: $2.12 to $2.18
• 50-Day Range: $1.99 to $3.28
• 52-Week Range: $1.98 to $20.00
• Volume: 10,939 shs
• Average Volume: 44,825 shs
• Market Capitalization: $16.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.83
• Consensus Rating: Moderate Buy

Allurion Technologies Stock Analysis - MarketRank™

Allurion Technologies scored higher than 44% of companies evaluated by MarketBeat, and ranked 788th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Allurion Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Allurion Technologies has a consensus price target of $22.83, representing about 969.0% upside from its current price of $2.14.

Amount of Analyst Coverage

Allurion Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Allurion Technologies are expected to grow in the coming year, from ($9.96) to ($7.39) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.58% of the float of Allurion Technologies has been sold short.

Short Interest Ratio / Days to Cover

Allurion Technologies has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allurion Technologies has recently increased by 25.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allurion Technologies does not currently pay a dividend.

Dividend Growth

Allurion Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.58% of the float of Allurion Technologies has been sold short.

Short Interest Ratio / Days to Cover

Allurion Technologies has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allurion Technologies has recently increased by 25.21%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: N/A

News Sentiment

Allurion Technologies has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Allurion Technologies this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Allurion Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Allurion Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.40% of the stock of Allurion Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 21.39% of the stock of Allurion Technologies is held by institutions.

ALUR Stock Analysis - Frequently Asked Questions

How have ALUR shares performed this year?

Allurion Technologies' stock was trading at $10.75 at the beginning of 2025. Since then, ALUR stock has decreased by 80.1% and is now trading at $2.1360.

How were Allurion Technologies' earnings last quarter?

Allurion Technologies, Inc. (NYSE:ALUR) announced its quarterly earnings results on Tuesday, August, 19th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.08. The business earned $3.38 million during the quarter, compared to analysts' expectations of $6.20 million.
Read the conference call transcript.

When did Allurion Technologies' stock split?

Allurion Technologies shares reverse split before market open on Friday, January 3rd 2025.The 1-25 reverse split was announced on Tuesday, December 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Allurion Technologies' major shareholders?

Allurion Technologies' top institutional investors include XTX Topco Ltd (0.25%).
View institutional ownership trends.

How do I buy shares of Allurion Technologies?

Shares of ALUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Allurion Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allurion Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Nuvation Bio (NUVB), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Amprius Technologies (AMPX) and Applied Digital (APLD).

Company Calendar

• Last Earnings: 8/19/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ALUR
• Previous Symbol: NYSE:ALUR
• CIK: 1964979
• Web: www.allurion.com
• Phone: 508-647-4000
• Fax: N/A
• Employees: 501
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Allurion Technologies: $22.83
• High Price Target: $50.00
• Low Price Target: $2.50
• Potential Upside/Downside: +955.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($12.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.20 million
• Net Margins: -158.30%
• Pretax Margin: -55.19%
• Return on Equity: N/A
• Return on Assets: -59.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.02
• Quick Ratio: 1.70

Sales & Book Value

• Annual Sales: $32.11 million
• Price / Sales: 0.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($30.08) per share
• Price / Book: -0.07

Miscellaneous

• Outstanding Shares: 7,760,000
• Free Float: 7,018,000
• Market Cap: $16.79 million
• Optionable: Optionable
• Beta: -0.46